Literature DB >> 24718812

Role of the p.E66Q variant of GLA in the progression of chronic kidney disease.

Hirofumi Watanabe1, Shin Goto, Akinori Miyashita, Hiroki Maruyama, Minako Wakasugi, Akio Yokoseki, Ryozo Kuwano, Ichiei Narita.   

Abstract

BACKGROUND: The p.E66Q variant of the α-galactosidase A gene (GLA) is frequently found during screening for Fabry disease in dialysis patients in Japan. However, recent reports suggest that the p.E66Q variant is not a disease-causing mutation but is a risk factor for cerebral small-vessel occlusion. To evaluate the role of the p.E66Q in the progression of renal diseases, we performed a genetic association study in patients with chronic kidney disease (CKD).
METHODS: In this study, we enrolled 1651 chronic hemodialysis and 941 non-dialysis patients who attended medical institutions in the Niigata Prefecture, Japan. The frequency of the p.E66Q allele was compared between hemodialysis and non-dialysis patients, with data from a previously published study of Japanese male newborns. In addition, we compared estimated glomerular filtration rates (eGFR) in the presence or absence of the p.E66Q variant in non-dialysis patients.
RESULTS: Of the 2233 alleles in hemodialysis and 1447 alleles in non-dialysis patients, 21 and nine harbored p.E66Q, respectively. However, p.E66Q allele frequencies did not differ between the two patient groups (0.90 versus 0.62 %, P = 0.35), and no significant difference in p.E66Q allele frequency was observed between male hemodialysis patients and the general Japanese population (0.52 versus 0.63 %, P = 0.67). Moreover, eGFR did not significantly differ between non-dialysis patients with the p.E66Q variant and patients with the wild-type allele (65.5 ± 10.7 versus 62.7 ± 16.6 mL/min/1.73 m(2), P = 0.69).
CONCLUSION: This study indicated that the p.E66Q variant of GLA does not affect the progression of CKD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718812     DOI: 10.1007/s10157-014-0969-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  18 in total

Review 1.  The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review.

Authors:  Y Kikumoto; H Sugiyama; H Morinaga; T Inoue; K Takiue; M Kitagawa; D Saito; Y Takatori; M Kinomura; S Kitamura; S Akagi; K Sada; K Nakao; Y Maeshima; H Kitayama; H Makino
Journal:  Clin Nephrol       Date:  2012-09       Impact factor: 0.975

2.  Significance of screening for Fabry disease among male dialysis patients.

Authors:  Mayuri Ichinose; Masaaki Nakayama; Toya Ohashi; Yasunori Utsunomiya; Masahisa Kobayashi; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.

Authors:  Masahisa Kobayashi; Toya Ohashi; Takahiro Fukuda; Tomoyoshi Yanagisawa; Takayuki Inomata; Takashi Nagaoka; Teruo Kitagawa; Yoshikatsu Eto; Hiroyuki Ida; Eiji Kusano
Journal:  Mol Genet Metab       Date:  2012-10-24       Impact factor: 4.797

4.  Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.

Authors:  M Tanaka; T Ohashi; M Kobayashi; Y Eto; N Miyamura; K Nishida; E Araki; K Itoh; K Matsushita; M Hara; K Kuwahara; T Nakano; N Yasumoto; H Nonoguchi; K Tomita
Journal:  Clin Nephrol       Date:  2005-10       Impact factor: 0.975

5.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

6.  Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.

Authors:  Takahito Inoue; Kiyoko Hattori; Kenji Ihara; Atsushi Ishii; Kimitoshi Nakamura; Shinichi Hirose
Journal:  J Hum Genet       Date:  2013-05-16       Impact factor: 3.172

7.  Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.

Authors:  T Okumiya; S Ishii; T Takenaka; R Kase; S Kamei; H Sakuraba; Y Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1995-09-25       Impact factor: 3.575

Review 8.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

9.  p.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males.

Authors:  K Nakamura; Y Sekijima; K Nakamura; K Hattori; K Nagamatsu; Y Shimizu; M Yazaki; A Sakurai; F Endo; Y Fukushima; S-I Ikeda
Journal:  Eur J Neurol       Date:  2013-05-31       Impact factor: 6.089

Review 10.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

View more
  3 in total

1.  Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.

Authors:  Masayoshi Oikawa; Nobuo Sakamoto; Atsushi Kobayashi; Satoshi Suzuki; Akiomi Yoshihisa; Takayoshi Yamaki; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Yuichirou Kiko; Hajime Nakano; Takeharu Hayashi; Akinori Kimura; Yasuchika Takeishi
Journal:  BMC Cardiovasc Disord       Date:  2016-05-10       Impact factor: 2.298

2.  Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST).

Authors:  Yumi Watanabe; Kaori Kitamura; Kazutoshi Nakamura; Kazuhiro Sanpei; Minako Wakasugi; Akio Yokoseki; Osamu Onodera; Takeshi Ikeuchi; Ryozo Kuwano; Takeshi Momotsu; Ichiei Narita; Naoto Endo
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-01-19

3.  Screening of Fabry disease in patients with chronic kidney disease in Japan.

Authors:  Akiko Nagata; Makoto Nasu; Yusuke Kaida; Yosuke Nakayama; Yuka Kurokawa; Nao Nakamura; Ryo Shibata; Takuma Hazama; Takahiro Tsukimura; Tadayasu Togawa; Seiji Saito; Hitoshi Sakuraba; Kei Fukami
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 5.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.